Organization | Y. R. Gaitonde Centre for AIDS Research and Education

Y. R. Gaitonde Centre for AIDS Research and Education Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2008

NCT00357552

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

YR Gaitonde Centre for AIDS Research and Education

Active Ingredients

Drugs in Phase 3 Trials (3)

daclatasvir (daklinza) (1 trial)

interferon alpha-2a (roferon-a) (1 trial)

sofosbuvir (sovaldi) (2 trials)

Drugs in Phase 2 Trials (2)

interferon alpha-2b (Intron-A) (1 trial)

ribavirin (virazole) (1 trial)

Drugs in Other Trials (4)

emtricitabine (emtriva) (1 trial)

lopinavir (Kaletra) (1 trial)

ritonavir (Norvir) (1 trial)

tenofovir (viread) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 9